Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

Macular Diseases

Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method

Acta Ophthalmol.

Cao J, You K, Jin K, Lou L, Wang Y, Chen M, Pan X, Shao J, Su Z, Wu J, Ye J

doi: 10.1111/aos.14514.

Macular Diseases

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Ophthalmology.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA

doi: 10.1016/j.ophtha.2017.10.010.

Macular DiseasesRetinal Diseases

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

Br J Ophthalmol

Szeto SK, Hui VWK, Tang FY, Yang D, Sun ZH, Mohamed S, Chan CKM, Lai TYY, Cheung C

doi: 10.1136/bjophthalmol-2021-319587

Retinal Diseases

Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Am J Ophthalmol.

Wubben TJ, Johnson MW, Anti-VEGF Treatment Interruption Study Group

doi: 10.1016/j.ajo.2019.03.005.

Retinal Diseases

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial

Retina.

Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata MÁ

doi: 10.1097/IAE.

COMMENTED

Macular Diseases

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial

★ 3 Recommended by Prof. Dr Daniel Barthelmes, Faculty Member

★ 3 Recommended and commented by Prof. Dr Stephan Michels, Faculty Member

JAMA Ophthalmol.

Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T

doi: 10.1001/jamaophthalmol.2019.5540.

COMMENTED

Macular Diseases

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems

★ 2 Recommended and commented by Prof. Dr Stephan Michels, Faculty Member

BMC Ophthalmol.

Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J

doi: 10.1186/s12886-020-01554-2.

COMMENTED

Macular Diseases

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration

★ 1 Recommended by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Sci Rep

Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, Thomet-Hunziker IP, Hatz K

doi: 10.1038/s41598-020-76354-1

COMMENTED

Macular Diseases

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Retina.

Arendt P, Yu S, Munk MR, Ebneter A, Wolf S, Zinkernagel MS

doi: 10.1097/IAE.

Related content

Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study

Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION